CA
CABA icon

CoreCap Advisors’s Cabaletta Bio CABA Stock Holding History

CoreCap Advisors’s Portfolio CABA Stock Details CABA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-151
Closed -$209 – 2836
2025
Q1 		$209 Buy
+151
New +$322 ﹤0.01% 2958

Other funds holding CABA

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HCM
Heights Capital Management San Francisco, California $359M AUM 7.93% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

CoreCap Advisors's CABA Position: Q2 2025 in Review

CoreCap Advisors sold out of Cabaletta Bio (CABA) in Q2 2025, closing a stake of 151 shares — an estimated $209 sold.

CoreCap Advisors first reported a position in CABA in Q1 2025 and held it in 1 quarter. The position peaked at $209 in Q1 2025. 86 funds tracked by Wall St. Rank hold CABA as of Q2 2025.

  • CoreCap Advisors reported no remaining Cabaletta Bio position as of Q2 2025 after selling out during the quarter.
  • CoreCap Advisors sold 151 Cabaletta Bio shares in Q2 2025, an estimated $209.
  • CoreCap Advisors first reported a position in Cabaletta Bio in Q1 2025 and held it in 1 quarter.
  • CoreCap Advisors's Cabaletta Bio position peaked at $209 in Q1 2025.
  • 86 funds tracked by Wall St. Rank held Cabaletta Bio as of Q2 2025.

Based on CoreCap Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.